Full-Time

Enterprise Security Lead

Confirmed live in the last 24 hours

Tempus

Tempus

1,001-5,000 employees

AI-driven healthcare data analysis platform

AI & Machine Learning
Biotechnology
Healthcare

Compensation Overview

$140k - $210kAnnually

+ Incentive Compensation + Restricted Stock Units

Senior, Expert

Company Historically Provides H1B Sponsorship

Chicago, IL, USA + 1 more

More locations: New York, NY, USA

This is a hybrid role, requiring some in-office presence.

Category
Cybersecurity
IT & Security

You match the following Tempus's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Proven expert-level knowledge and experience in one or more specific domains, such as Microsoft Security, Endpoint Security, or Network Security.
  • Minimum 7-10 years of experience in Information Technology, with a strong understanding of security principles and best practices.
  • Excellent communication, collaboration, and interpersonal skills.
  • Ability to translate technical security concepts into clear and concise language for both technical and non-technical audiences.
  • Strong analytical and problem-solving skills.
  • Experience working in a collaborative environment with IT and other business units.
  • Experience with security frameworks like NIST CSF, CIS Controls, or ISO 27001 (a plus).
  • Experience with security tools and technologies relevant to the scope of the role (a plus).
Responsibilities
  • Provide strategic vision and leadership for the Enterprise Security team, defining security priorities and aligning them with overall business objectives.
  • Oversee the design, implementation, and maintenance of comprehensive security solutions across various domains, including Microsoft Security, Endpoint Security, Server Security, Network Security, Asset Management, Device Assurance, Zero Trust Security, PKI, and Compliance.
  • Lead the development and implementation of security policies, procedures, and standards, ensuring they are aligned with industry best practices and regulatory requirements.
  • Guide and mentor Enterprise Security team members, fostering a collaborative environment that promotes continuous learning and professional development.
  • Identify, assess, and mitigate security risks, proactively addressing potential threats and vulnerabilities.
  • Collaborate with IT and other business units to promote security awareness and integrate security best practices into operational processes.
  • Develop and implement a communication strategy to inform stakeholders of security risks, updates, and best practices.
  • Track key security metrics and report on the overall effectiveness of the security program.
Desired Qualifications
  • Experience with security frameworks like NIST CSF, CIS Controls, or ISO 27001 (a plus).
  • Experience with security tools and technologies relevant to the scope of the role (a plus).

Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in the healthcare sector. The company offers a platform that analyzes medical data, helping physicians make better treatment decisions by providing insights from medical images and identifying care gaps. For pharmaceutical and biotech companies, Tempus aids in drug development by discovering new targets and assessing treatment effectiveness. Patients benefit from personalized therapy options identified through the platform. Tempus also conducts significant research, particularly in cancer, and has developed tools like a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. Unlike many competitors, Tempus combines extensive data analysis with a focus on personalized medicine, aiming to improve care and treatment options for patients.

Company Size

1,001-5,000

Company Stage

IPO

Total Funding

$894.9M

Headquarters

Chicago, Illinois

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • Tempus' AI platform aids in personalized cancer treatment and drug development.
  • The Olivia app empowers patients with AI-driven health management tools.
  • Partnerships with firms like Genialis expand Tempus' diagnostic capabilities.

What critics are saying

  • Over-reliance on AI may lead to misinterpretation of medical data.
  • Data privacy concerns arise with the Olivia app's extensive health system integration.
  • Regulatory challenges may hinder the global rollout of Tempus' xT CDx test.

What makes Tempus unique

  • Tempus uses AI to provide personalized treatment insights for cancer patients.
  • Their platform integrates clinical and molecular data for precision medicine.
  • Tempus collaborates with biotech firms to enhance drug development and diagnostics.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Relocation Assistance

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

1%
Hit Consultant
Feb 21st, 2025
Stemline Therapeutics To Deploy Tempus Next’S Ai-Enabled Care Pathway Intelligence Platform

Stemline Therapeutics to Deploy Tempus Next’s AI-Enabled Care Pathway Intelligence Platform. by Fred Pennic 02/21/2025 Leave a Comment. What You Should Know: – Tempus, a provider of AI-driven precision medicine, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group announced a new collaboration to improve the use of ESR1 testing in metastatic breast cancer (mBC). – The partnership will leverage Tempus’ Next platform, an AI-enabled care pathway intelligence tool, to help clinicians determine when ESR1 testing may be appropriate for their patients.Challenges in ESR1 TestingESR1 mutations are a critical factor in the progression of ER+/HER2- mBC, a common type of breast cancer. Up to 50% of patients with this type of cancer can develop ESR1 mutations after prior endocrine therapy. Recognizing this, the American Society of Clinical Oncology (ASCO) recommends ESR1 mutation testing at each disease progression. Tempus Next: Guiding Clinical DecisionsTempus’ Next platform will analyze clinical data from mBC patients and notify clinicians when ESR1 testing is missing at disease progression

ETF Daily News
Feb 15th, 2025
Apollon Wealth Management LLC Makes New $256,000 Investment in Tempus AI, Inc. (NASDAQ:TEM)

Apollon Wealth Management LLC makes new $256,000 Investment in Tempus AI, Inc. (NASDAQ:TEM).

Money Morning
Feb 14th, 2025
Nancy Pelosi's Favorite AI Stock Rising Again After 13% Surge

Tempus announced yesterday that it was collaborating with the nonprofit Institute for Follicular Lymphoma Innovation to develop treatment options for patients with the disease.

Medical Device Network
Feb 13th, 2025
Artera partners with Tempus to expand AI cancer test access

Currently connected to more than 50% of all oncologists practising in the US, Chicago-based Tempus will work with Artera on an exclusive basis to commercialise the latter's ArteraAI prostate test.

TipRanks
Feb 13th, 2025
Tempus AI enters collaboration with Institute for Follicular Lymphoma Innovation

Tempus AI (TEM) announced a new collaboration with the Institute for Follicular Lymphoma Innovation.